Source Capital Invests in CTL Amedica

Source Capital, through Source Capital Credit Opportunities Fund III, LP (“SCCO III”), is pleased to announce its investment in CTL Amedica (the “Company”), a leading designer, manufacturer and distributor of spinal fusion and fixation products and tooling. SCCO III provided debt financing to recapitalize the Company and provide growth funding as the Company continues to build out its product portfolio.

Headquartered in Dallas, TX, CTL has developed a robust product portfolio of patented spinal devices, incorporating differentiated materials and surface technologies. CTL is the only company in the world that offers silicon nitride implants in spine, which has the ability to achieve superior new bone growth, along with demonstrated bacteriostatic properties and enhanced imaging attributes. CTL’s in-house engineering and manufacturing capabilities allow the Company to rapidly bring new products to the market and support hundreds of surgeons across the U.S.

“CTL has built an impressive portfolio of spinal products, and we are excited to partner with the management team and support the Company as it continues to innovate and bring new products to the market,” said Joe Rodgers, Managing Director at Source Capital.

To learn more about CTL Amedica, please visit:


About Source Capital, LLC
Source Capital is a private investment firm focused on providing flexible equity and debt capital to lower middle-market companies across a range of industries. Source Capital’s investment strategy targets growing companies with greater than $2 million in EBITDA seeking a growth-oriented partner. Since its founding in 2002, Source Capital has made 23 equity platform investments, 44 add-on acquisitions and 33 debt investments through three separate credit funds.  To learn more about Source Capital or to discuss a new equity or debt investment opportunity, please reach out to a member of our investment team.


© 2019 Source Capital | All Rights Reserved. Web design & development by James Ross Advertising. | Disclaimer